Neuroblastomas with chromosome 11q loss and single copy MYCN comprise a biologically distinct group of tumours with adverse prognosis

Neuroblastoma is a heterogeneous tumour and its effective clinical management is dependent on accurate prognostic evaluation. In approximately 25% of patients amplification of the MYCN oncogene is known to be associated with a poor outcome. In order to identify additional molecular markers with prognostic potential in non-MYCN-amplified neuroblastomas, we looked for a correlation between clinical outcome and loss of heterozygosity (LOH) on four chromosomes that frequently show alteration in neuroblastoma (chromosomes 3, 4, 11 and 14). Chromosome 11q loss (with frequent parallel loss of chromosomes 3p, 4p and/or 14q) was found exclusively in tumours without MYCN amplification and was significantly associated with poor event-free survival. The 2-year event-free survival rate for 11q LOH cases was 30%, compared to 34% for MYCN-amplified cases and 100% for cases without these abnormalities. While 11q LOH was associated predominantly with advanced-stage disease, 2 cases with low-stage disease and 11q LOH both suffered relapses. We conclude that chromosome 11q loss defines a biologically distinct group of tumours without MYCN amplification that appear to have potential for aggressive metastatic growth. Thus this genetic alteration may be an important new prognostic marker in neuroblastoma. © 2001 Cancer Research Campaign http://www.bjcancer.com

[1]  Jörg Michaelis,et al.  Neuroblastoma in Europe: differences in the pattern of disease in the UK , 1998, The Lancet.

[2]  F. Speleman,et al.  Evidence for two tumour suppressor loci on chromosomal bands 1p35-36 involved in neuroblastoma: one probably imprinted, another associated with N-myc amplification. , 1995, Human molecular genetics.

[3]  P. Ambros,et al.  Connatal localized neuroblastoma: The case to delay treatment , 1996, Cancer.

[4]  H. Caron,et al.  Allelic loss of chromosome 1 and additional chromosome 17 material are both unfavourable prognostic markers in neuroblastoma. , 1995, Medical and pediatric oncology.

[5]  F. Berthold,et al.  The 1p deletion is not a reliable marker for the prognosis of patients with neuroblastoma. , 1995, Cancer research.

[6]  G. Thomas,et al.  Two distinct deleted regions on the short arm of chromosome I in neuroblastoma , 1994, Genes, chromosomes & cancer.

[7]  Nick Bown,et al.  Comparative genomic hybridization study of primary neuroblastoma tumors , 1997, Genes, chromosomes & cancer.

[8]  G. Brodeur.  Molecular basis for heterogeneity in human neuroblastomas. , 1995, European journal of cancer.

[9]  R. Simon,et al.  Comparative genomic hybridization and telomerase activity analysis identify two biologically different groups of 4s neuroblastomas. , 1998, British Journal of Cancer.

[10]  F. Speleman,et al.  Genetic heterogeneity of neuroblastoma studied by comparative genomic hybridization , 1998, Genes, chromosomes & cancer.

[11]  R. Seeger,et al.  Deletion of chromosome 11 and of 14q sequences in neuroblastoma , 1993, Genes, chromosomes & cancer.

[12]  N C Dracopoli,et al.  Loss of heterozygosity for the short arm of chromosome 1 in human neuroblastomas: correlation with N-myc amplification. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[13]  J. Maris,et al.  Biology and genetics of human neuroblastomas. , 1997, Journal of pediatric hematology/oncology.

[14]  F. Lampert,et al.  Sublocalization of putative tumor suppressor gene loci on chromosome arm 14q in neuroblastoma , 1999, Genes, chromosomes & cancer.

[15]  G. Thomas,et al.  Clinical relevance of loss of heterozygosity of the short arm of chromosome 1 in neuroblastoma: A single‐institution study , 1996, International journal of cancer.

[16]  J. Yokota,et al.  Frequent loss of heterozygosity on chromosome 14q in neuroblastoma. , 1989, Cancer research.

[17]  K. Matthay,et al.  Gain of chromosome 17 is the most frequent abnormality detected in neuroblastoma by comparative genomic hybridization. , 1997, The American journal of pathology.

[18]  N. Shimizu,et al.  Detailed deletion mapping of chromosome band 14q32 in human neuroblastoma defines a 1.1-Mb region of common allelic loss , 2000, British Journal of Cancer.

[19]  H. Aburatani,et al.  Loss of heterozygosity of 3p markers in neuroblastoma tumours implicate a tumour-suppressor locus distal to the FHIT gene. , 1998, British Journal of Cancer.

[20]  F. Berthold,et al.  Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. , 1993, Progress in clinical and biological research.

[21]  F. Speleman,et al.  Deletion mapping in neuroblastoma cell lines suggests two distinct tumor suppressor genes in the 1p35-36 region, only one of which is associated with N-myc amplification. , 1995, Oncogene.

[22]  C. Sapienza,et al.  Loss of heterozygosity for chromosomes 1 or 14 defines subsets of advanced neuroblastomas. , 1992, Cancer research.

[23]  D. Stram,et al.  Deletion of 11q23 is a frequent event in the evolution of MYCN single-copy high-risk neuroblastomas. , 2000, Medical and pediatric oncology.

[24]  A. Look,et al.  Significance of chromosome 1p loss of heterozygosity in neuroblastoma. , 1995, Cancer research.

[25]  W. Gerald,et al.  Clinical categories of neuroblastoma are associated with different patterns of loss of heterozygosity on chromosome arm 1p. , 2000, The Journal of molecular diagnostics : JMD.

[26]  F. Speleman,et al.  Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. , 1999, The New England journal of medicine.

[27]  D. Stram,et al.  Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas , 1999, Oncogene.

[28]  M. Schwab,et al.  There may be two tumor suppressor genes on chromosome arm Ip closely associated with biologically distinct subtypes of neuroblastoma , 1994, Genes, chromosomes & cancer.